-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Distal Symmetric Polyneuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ricolinostat in Distal Symmetric Polyneuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Distal Symmetric Polyneuropathy Drug Details: Ricolinostat (ACY-1215) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Diabetic Neuropathic Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ricolinostat in Diabetic Neuropathic Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Diabetic Neuropathic Pain Drug Details: Ricolinostat (ACY-1215) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Chemotherapy Induced Peripheral Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ricolinostat in Chemotherapy Induced Peripheral Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Chemotherapy Induced Peripheral Neuropathy Drug Details: Ricolinostat (ACY-1215)...
-
Product Insights
Chemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hemoglobinopathies – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemoglobinopathies - Drugs In Development, 2023’, provides an overview of the Hemoglobinopathies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemoglobinopathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Charcot-Marie-Tooth Disease Type II – Drugs In Development, 2023
Global Markets Direct’s, ‘Charcot-Marie-Tooth Disease Type II - Drugs In Development, 2023’, provides an overview of the Charcot-Marie-Tooth Disease Type II pipeline landscape. The report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type II, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Polycystic Kidney Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycystic Kidney Disease - Drugs In Development, 2023’, provides an overview of the Polycystic Kidney Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Peripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Neuropathy (Sensory Neuropathy) - Drugs In Development, 2023’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Charcot-Marie-Tooth Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Charcot-Marie-Tooth Disease - Drugs In Development, 2023’, provides an overview of the Charcot-Marie-Tooth Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thalassemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Thalassemia - Drugs In Development, 2023’, provides an overview of the Thalassemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...